Showing 2801-2810 of 3448 results for "".
- Health-Conscious Women 60% More Likely to Prefer Expensive Brand-Name Drugshttps://practicaldermatology.com/news/20121025-health-conscious_women_60_more_likely_to_prefer_expensive_brand-name_drugs/2459691/The consumer market research firm Scarborough analyzed "Health-Conscious Women," defined by Scarborough as American adult women who agree that they go to the doctor regularly for checkups, generally feel they eat right, and follow a regular exercise routine. Health-Conscious Women make up 16 percent
- FDA Extends Action Date For Tofacitinib New Drug Application By Three Monthshttps://practicaldermatology.com/news/20120824-us_food_and_drug_administration_extends_action_date_for_tofacitinib_new_drug_application_by_three_months/2459748/
- ICONIC-LEAD: Durable Psoriasis Clearance Through 52 Weeks with Icotrokinrahttps://practicaldermatology.com/news/new-icotrokinra-data-shows-durable-psoriasis-clearance-through-52-weeks/2486414/The US Food and Drug Administration (FDA) recently granted approval for the oral interleukin (IL)-23 receptor antagonist icotrokinra (ICOTYDE™, Johnson & Johnson) for patients aged 12 years and older with moderate-to-severe plaque psoriasis who are candidates f
- FDA Expands Secukinumab to Adolescents With Moderate to Severe HShttps://practicaldermatology.com/news/fda-expands-secukinumab-to-adolescents-with-moderate-to-severe-hs/2486084/The US Food and Drug Administrationv (FDA) has approved secukinumab (Cosentyx, Novartis) for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa (HS), becoming the only IL-17A inhibitor approved for this group, according to a
- Sotyktu Gets FDA Nod as First TYK2 Inhibitor for Psoriatic Arthritishttps://practicaldermatology.com/news/sotyktu-gains-fda-approval-as-first-tyk2-inhibitor-for-psoriatic-arthritis/2486046/The US Food and Drug Administration (FDA) has approved deucravacitinib (Sotyktu; Bristol Myers Squibb) for the treatment of adults with active psoriatic arthritis (PsA), representing the first oral therapy in its class approved for the treatment of the condition, a
- Phase 3: QTORIN™ Rapamycin Meets All Primary, Secondary Endpoints in Microcystic Lymphatic Malformationshttps://practicaldermatology.com/news/phase-3-qtorin-rapamycin-meets-all-primary-secondary-endpoints-in-microcystic-lymphatic-malformations/2485806/Palvella Therapeutics, Inc. announced positive topline results from the Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations (microcystic LMs), a rare, congenital vascular anomaly with no US Food and Drug Admin
- Analysis: Biologics Linked to Lower Cardiometabolic Risk in HShttps://practicaldermatology.com/news/analysis-biologics-linked-to-lower-cardiometabolic-risk-in-hs/2485805/Biologics were associated with a lower incidence of type 2 diabetes mellitus (T2DM) and cardiovascular events vs. no biologic use in a TriNetX cohort of 291,283 patients with hidradenitis suppurativa (HS), according to a new study in the Journal of Drugs in Dermatology. Investigat
- FDA Accepts Galderma’s RelabotulinumtoxinA BLA Resubmissionhttps://practicaldermatology.com/news/fda-accepts-galdermas-relabotulinumtoxina-bla-resubmission/2485601/Galderma announced that the US Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application (BLA) for relabotulinumtoxinA (Relfydess™) for the temporary improvement of moderate-to-severe glabellar lines and lateral canthal lines in a
- Analysis: ChatGPT and DeepSeek Largely Align With Psoriasis Treatment Guidelineshttps://practicaldermatology.com/news/analysis-chatgpt-and-deepseek-largely-align-with-psoriasis-treatment-guidelines/2485578/Large language models (LLMs) ChatGPT and DeepSeek generally adhere to established psoriasis treatment guidelines, but some performance gaps remain. Investigators publishing in the Journal of Drugs in Dermatology exp
- AbbVie Files FDA, EMA Applications for Upadacitinib in Non-Segmental Vitiligohttps://practicaldermatology.com/news/abbvie-files-fda-ema-applications-for-upadacitinib-in-non-segmental-vitiligo/2485564/AbbVie has submitted regulatory applications to the US Food and Drug Administration and European Medicines Agency seeking approval of upadacitinib (RINVOQ) for the treatment of adults and adolescents with non-segmental vitiligo (NSV), according to a